NextCure (NASDAQ:NXTC) had its price objective lifted by Morgan Stanley from $25.00 to $33.00 in a research report sent to investors on Tuesday morning, AnalystRatings.com reports. Morgan Stanley currently has an overweight rating on the stock.

Other equities analysts also recently issued reports about the stock. Piper Jaffray Companies assumed coverage on shares of NextCure in a research note on Monday, June 3rd. They set an overweight rating and a $26.00 price objective on the stock. Bank of America assumed coverage on shares of NextCure in a research note on Tuesday, July 9th. They set a buy rating and a $25.00 price objective on the stock.

Shares of NASDAQ:NXTC opened at $26.71 on Tuesday. The stock’s 50 day moving average is $18.87. NextCure has a one year low of $13.86 and a one year high of $27.89.

NextCure (NASDAQ:NXTC) last issued its earnings results on Monday, August 12th. The company reported ($0.61) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.15). The firm had revenue of $1.40 million for the quarter, compared to analyst estimates of $1.50 million. As a group, research analysts anticipate that NextCure will post -2.14 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NXTC. Sofinnova Investments Inc. bought a new position in shares of NextCure during the second quarter valued at approximately $37,777,000. Matthews International Capital Management LLC bought a new position in shares of NextCure during the second quarter valued at approximately $6,741,000. Fosun International Ltd bought a new position in shares of NextCure during the second quarter valued at approximately $2,247,000. BlackRock Inc. bought a new position in shares of NextCure during the second quarter valued at approximately $2,032,000. Finally, Yale University bought a new position in shares of NextCure during the second quarter valued at approximately $1,865,000. Hedge funds and other institutional investors own 2.06% of the company’s stock.

NextCure Company Profile

There is no company description available for NextCure Inc

Further Reading: Why are trading ranges significant?

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.